Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Imiquimod vs Conization for CIN 2/3
NCT01283763Phase 3Terminated
- Sponsor
- Medical University of Vienna
- Start
- May 2013
- Primary completion
- Sep 2017
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of imiquimod in cervical intraepithelial neoplasia (CIN) (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Rate of successful treatment defined as negative HPV test result at 6 months. Started May 2013; status: terminated.
02
Drugs
imiquimod
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT01283763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01283763.